New Vaccine Recommendations from the AAP
The American Academy of Pediatrics (AAP) made headlines on Tuesday with its latest vaccine recommendations. The guidance suggests that children between 6 months and 23 months should receive COVID-19 vaccinations unless they have specific allergies to the ingredients. Additionally, older kids should also get vaccinated if they’re at an increased risk of spreading the virus to vulnerable populations facing COVID-related complications.
This stance contrasts with the Centers for Disease Control and Prevention (CDC), which advocates for a more nuanced approach—encouraging “shared decision-making” among parents and healthcare providers regarding vaccination for children 6 months and older.
In response, Andrew Nixon, the communications director for the Department of Health and Human Services (HHS), accused the AAP of “undermining national immunization policymaking” due to their differing recommendations. He emphasized that HHS Secretary Robert F. Kennedy Jr. remains dedicated to upholding scientific integrity, transparency, and rebuilding public trust.
On another note, the Integrity Project is set to gather data related to vaccine safety and efficacy, particularly for older adults at a higher risk of hospitalization and death from infections. They are working on a searchable website to help individuals find information about vaccine safety and effectiveness across various demographic groups.
The focused analysis of recent studies has some limitations. However, researchers have found significant evidence supporting the effectiveness of the nirsevimabc vaccine in preventing hospitalizations and medical issues related to RSV in children. Unfortunately, the recent studies did not provide data on safety or effectiveness for clesrovimab, another federally recommended antibody therapy aimed at reducing RSV risks.
On a related note, the analysis confirms previous findings regarding a potential risk of myocarditis—inflammation of the heart muscle—associated with COVID-19 vaccines in children. Dr. Harleen Marwah, a pediatrician at Massachusetts General Brigham for Children, shared that the risk seems to be highest after the second dose, tapering off with subsequent doses. One specific study indicated that there could be up to three cases of myocarditis per 100,000 recipients, primarily affecting males who received the Pfizer vaccine.
